Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.40 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.40 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 6/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | Q9HBH1 | 1/20 | 0.34 | |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29696200 | 1.00 | CA2 (0.42) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL66399 | 1.00 | CA2 (0.42) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL31407436 | 0.95 | GRIK1 (0.41) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL8460619 | 0.95 | GRIK1 (0.41) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL25177958 | 0.94 | GRIK1 (0.43) | CA2SLC1A2SLC1A1MEN1KMT2A | |
| SCHEMBL66573 | 0.90 | HDAC1 (0.41) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL20826464 | 0.90 | HDAC1 (0.41) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL67491 | 0.90 | HDAC1 (0.41) | CA2MAPK1SLC1A2SLC1A1SLC1A3 | |
| SCHEMBL27041531 | 0.87 | MEN1 (0.37) | MEN1GAAKMT2AMMP13 | |
| SCHEMBL27041525 | 0.87 | MEN1 (0.37) | MEN1GAAKMT2AMMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PEPTIDREAM INC (JP) | 2026-01-15 | — | — | US | disclosed |
| US-20250281433-A1 | NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME | AMTIXBIO CO., LTD. (KR) | 2025-09-11 | — | — | US | disclosed |
| EP-4534524-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | PeptiDream Inc. (JP) | 2025-04-09 | — | — | EP | disclosed |
| US-12180139-B2 | Method for preparing aminoalkanoic acid derivative containing biphenyl group | AMTIXBIO CO., LTD. (KR) | 2024-12-31 | — | — | US | disclosed |
| US-12172945-B2 | Aminoalkanoic acid derivative containing biphenyl group and use of the same | AMTIXBIO CO., LTD. (KR) | 2024-12-24 | — | — | US | disclosed |
| US-12129220-B2 | Pharmaceutical composition comprising aminoalkanoic acid derivative containing biphenyl group | AMTIXBIO CO., LTD. (KR) | 2024-10-29 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| EP-3992177-B1 | DERIVATIVE COMPOUND INTRODUCING BIPHENYL GROUP INTO NOVEL AMINOALKANOIC ACID AND ANTIFUNGAL PHARMACEUTICAL COMPOSITION COMPRISING SAME | AMTIXBIO CO LTD (KR) | 2024-05-08 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| EP-4268811-A1 | NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME | Amtixbio Co., Ltd. (KR) | 2023-11-01 | — | — | EP | disclosed |
| WO-2011149995-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA [C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-12-01 | — | — | WO | disclosed |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2011-11-17 | — | — | US | disclosed |
| EP-2367790-A2 | SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010062927-A2 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA(C)PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-06-03 | — | — | WO | disclosed |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-05-27 | — | — | US | disclosed |
| EP-0266950-B1 | Nor-statine and nor-cyclostatine polypeptides | PFIZER (US) | 1993-12-29 | — | — | EP | disclosed |
| US-5034376-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1991-07-23 | — | — | US | disclosed |
| US-4935405-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1990-06-19 | — | — | US | disclosed |
| US-4814342-A | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1989-03-21 | — | — | US | disclosed |
| EP-0266950-A2 | Nor-statine and nor-cyclostatine polypeptides | PFIZER INC. (US) | 1988-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12172945-B2 | Aminoalkanoic acid derivative containing biphenyl group and use of the same | GABBR1, AADAC, GABBR2 | CA2 766/4885MAPK1 3514/4885SLC1A2 143/4885 |
| US-20100130558-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CA2 138/4885MAPK1 1472/4885SLC1A2 234/4885 |
| US-20260015313-A1 | AMINO ACID ACTIVE ESTER AND SALT THEREOF | NSUN3, BCAT1, SLC43A1 | CA2 1024/4885MAPK1 1980/4885SLC1A2 218/4885 |
| US-20110281870-A1 | NOVEL SUBSTITUTED OCTAHYDROCYCLOPENTA[C]PYRROL-4-AMINES AS CALCIUM CHANNEL BLOCKERS | CACNA1C, ORAI1, CACNA1S | CA2 138/4885MAPK1 1472/4885SLC1A2 234/4885 |
| US-12180139-B2 | Method for preparing aminoalkanoic acid derivative containing biphenyl group | AKR7A2, CYP51A1, APEH | CA2 1098/4885MAPK1 3918/4885SLC1A2 249/4885 |
| US-20250281433-A1 | NOVEL DERIVATIVE COMPOUND HAVING BIPHENYL GROUP INTRODUCED INTO AMINO-ALKANOIC ACID AND ANTI-INFLAMMATORY COMPOSITION COMPRISING SAME | AADAT, AADAC, AHR | CA2 1311/4885MAPK1 1755/4885SLC1A2 510/4885 |
| US-12129220-B2 | Pharmaceutical composition comprising aminoalkanoic acid derivative containing biphenyl group | AHR, AADAC, GABBR1 | CA2 852/4885MAPK1 4069/4885SLC1A2 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.